HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Marketing In Brief

This article was originally published in The Rose Sheet

Executive Summary

Calvin Klein fragrance: Limited-edition ck One scene is a unisex scent that "energizes yet comforts," according to Unilever Cosmetics International. On counters in November, scene contains top notes of mandarin, ylang and ginger root, which blend to rosewood, ginger softact and muguet. Drydown includes musk, amberwoods and vanilla amber. Scent will be available in a 3.4 oz. edt spray for $40, as well as body wash ($15) and moisturizer ($20). The juice will be housed in cK's traditional flask-shaped bottle but will feature images of individuals and couples, "creating an eye-catching bodies-in-motion effect," Unilever says...

You may also be interested in...



P&G MAX Factor Restage Aims To Modernize 100-Year Old Brand

Procter & Gamble is relaunching its MAX Factor cosmetics brand this spring with new products, packaging and an advertising campaign starring actress Carmen Electra as part of an effort to modernize the 100-year old brand. The firm unveiled the new look during a Jan. 31 press event in New York City

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel